Free Access
Med Sci (Paris)
Volume 24, Number 12, Décembre 2008
Page(s) 1071 - 1076
Section M/S revues
Published online 15 December 2008
  1. Baldwin RW. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer 1966; 1 : 257–64. [Google Scholar]
  2. Baldwin RW. An immunological approach to cancer. Lav Ist Anat Istol Patol Univ Studi Perugia 1968; 28 : 65–85. [Google Scholar]
  3. Baldwin RW. Tumour-associated antigens and tumour-host interactions. Proc R Soc Med 1971; 64 : 1039–42. [Google Scholar]
  4. Machour N, Gilbert D, Vittecoq O, et al. Protéomique et autoanticorps. Med Sci (Paris) 2005; 21 : 759–64. [Google Scholar]
  5. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005; 4 : 1123–33. [Google Scholar]
  6. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Nal Acad Sci USA 1995; 92 : 11810–3. [Google Scholar]
  7. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94 : 1914–8. [Google Scholar]
  8. Tureci O, Mack U, Luxemburger U, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006; 236 : 64–71. [Google Scholar]
  9. Fossa A, Berner A, Fossa SD, et al. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59 : 440–7. [Google Scholar]
  10. Maio M, Coral S, Sigalotti L, et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003; 88 : 748–54. [Google Scholar]
  11. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187 : 1349–54. [Google Scholar]
  12. Park S, Lim Y, Lee D, et al. Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 2003; 1625 : 173–82. [Google Scholar]
  13. Jager D, Stockert E, Gure AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001; 61 : 2055–61. [Google Scholar]
  14. Di Modugno F, Bronzi G, Scanlan MJ, et al., Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004; 109 : 909–18. [Google Scholar]
  15. Pallasch CP, Struss AK, Munnia A, et al., Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005; 117 : 456–9. [Google Scholar]
  16. Prasannan L, Misek DE, Hinderer R, et al., Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000; 6 : 3949–56. [Google Scholar]
  17. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001; 98 : 9824–9. [Google Scholar]
  18. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1 : 890–8. [Google Scholar]
  19. Lichtenfels R, Kellner R, Atkins D, et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003; 1646 : 21–31. [Google Scholar]
  20. Lichtenfels R, Kellner R, Bukur J, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002; 2 : 561–70. [Google Scholar]
  21. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003; 3 : 45–55. [Google Scholar]
  22. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12 : 6415–20. [Google Scholar]
  23. Yang F, Xiao ZQ, Zhang XZ, et al., Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007; 6 : 751–8. [Google Scholar]
  24. Le Naour F, Brichory F, Misek DE, et al. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002; 1 : 197–203. [Google Scholar]
  25. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004; 64 : 5504–10. [Google Scholar]
  26. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001; 7 : 3328–35. [Google Scholar]
  27. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003; 21 : 37–8. [Google Scholar]
  28. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382 : 669–78. [Google Scholar]
  29. Gagnon A, Kim JH, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008; 14 : 764–71. [Google Scholar]
  30. Feng Y, Ke X, Ma R, et al. Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 2004; 50 : 416–22. [Google Scholar]
  31. Mattoon D, Michaud G, Merkel J, et al. Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev Proteomics 2005; 2 : 879–89. [Google Scholar]
  32. Ehrlich JR, Qin S, Liu BC. The reverse capture autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006; 1 : 452–60. [Google Scholar]
  33. Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3 : 56–63. [Google Scholar]
  34. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353 : 1224–35. [Google Scholar]
  35. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004; 3 : 261–7. [Google Scholar]
  36. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003; 3 : 2108–15. [Google Scholar]
  37. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18 : 868–73. [Google Scholar]
  38. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003; 9 : 5120–6. [Google Scholar]
  39. Zhong L, Peng X, Hidalgo GE, et al. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004; 4 : 1216–25. [Google Scholar]
  40. Lucchi G, Hendra JB, Pecqueur D, Ducoroy P. Vers une standardisation des outils pour les études de protéomique clinique. Med Sci (Paris) 2007; 23 (suppl 1) : 19–22. [Google Scholar]
  41. Solary E. Protéomique clinique en oncologie. Med Sci (Paris) 2007; 23 (suppl 1) : 3–4. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.